Danske Bank A S Grows Holdings in Medtronic PLC $MDT

Danske Bank A S boosted its holdings in Medtronic PLC (NYSE:MDT) by 11.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 841,228 shares of the medical technology company’s stock after purchasing an additional 86,433 shares during the quarter. Danske Bank A S’s holdings in Medtronic were worth $80,808,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Medtronic by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock valued at $12,388,027,000 after purchasing an additional 1,888,381 shares during the last quarter. State Street Corp raised its position in Medtronic by 1.0% in the 3rd quarter. State Street Corp now owns 60,460,537 shares of the medical technology company’s stock valued at $5,800,550,000 after purchasing an additional 625,992 shares during the last quarter. Bank of New York Mellon Corp raised its position in Medtronic by 0.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock valued at $2,044,637,000 after purchasing an additional 192,410 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Medtronic by 0.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock valued at $2,008,278,000 after purchasing an additional 98,220 shares during the last quarter. Finally, Raymond James Financial Inc. raised its position in Medtronic by 3.0% in the 3rd quarter. Raymond James Financial Inc. now owns 11,203,865 shares of the medical technology company’s stock valued at $1,067,055,000 after purchasing an additional 327,899 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

Shares of MDT opened at $81.07 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The stock has a market capitalization of $104.09 billion, a P/E ratio of 22.58, a P/E/G ratio of 2.06 and a beta of 0.75. The company’s fifty day moving average is $88.44 and its two-hundred day moving average is $94.82. Medtronic PLC has a 1 year low of $78.91 and a 1 year high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts predict that Medtronic PLC will post 5.57 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.5%. Medtronic’s dividend payout ratio is 79.11%.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.26% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on MDT. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Robert W. Baird upped their price target on shares of Medtronic from $92.00 to $93.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. CICC Research began coverage on shares of Medtronic in a research note on Friday, January 30th. They issued an “outperform” rating on the stock. Piper Sandler dropped their price objective on shares of Medtronic from $105.00 to $91.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 1st. Finally, Weiss Ratings cut shares of Medtronic from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, April 21st. Fifteen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $107.80.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA clearance for a next‑generation mitral valve expands Medtronic’s structural‑heart portfolio and could boost procedure volumes and long‑term revenue. Medtronic wins FDA nod for next-gen mitral valve
• Positive Sentiment: CE mark for the Stealth AXiS surgical robot platform supports earlier commercial rollout in Europe and strengthens Medtronic’s surgical robotics / navigation offering. This is a commercialization milestone that can accelerate adoption outside the U.S. Medtronic wins CE mark for Stealth AXiS surgical robot platform
• Positive Sentiment: Affera-related wins (FDA Breakthrough Device for Sphere‑9 and CE activity) and Medtronic’s progress on its cardiac ablation platform signal potential expansion into more complex arrhythmia treatments — a sizeable high‑margin market if commercialized broadly. Affera Breakthrough: FDA Nod For Sphere-9 Could Be A Game Changer For Medtronic (MDT)
• Positive Sentiment: Enrollment of the first patient in a post‑approval study for the Altaviva tibial neuromodulation device supports ongoing evidence generation and reimbursement positioning for a therapy targeting chronic indications — helps defend adoption and payer coverage. Medtronic enrolls first patient in post-approval study of Altaviva tibial neuromod
• Positive Sentiment: Market research reports for wearables and continuous glucose monitoring (Australia, Saudi Arabia, Middle East/Africa) highlight long‑term TAM expansion in remote monitoring and diabetes care — areas where Medtronic has product exposure. These macro tailwinds support growth prospects for MDT’s diabetes & connected devices businesses. Australia Wearable Medical Devices Market Trends and Forecasts Saudi Arabia Wearable Medical Devices Market Trends and Forecasts Middle East and Africa Continuous Glucose Monitoring Market Forecast
• Neutral Sentiment: Analysts’ opinions are mixed on MDT — some see valuation upside once execution stabilizes, others flag near‑term headwinds. Mixed analyst coverage tends to increase volatility but doesn’t change fundamentals immediately. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Neutral Sentiment: Industry moves (e.g., Teleflex CEO appointment) and FDA Breakthrough designations for other companies (Orchestra BioMed) are sector context items — they can affect competitive dynamics but are not direct Medtronic news. Teleflex Appoints Jason Weidman as President and CEO FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
• Negative Sentiment: UBS and Jefferies have trimmed their views/price targets after changes in Medtronic’s diabetes unit and model updates — analyst downgrades can pressure the stock and signal investor concern on near‑term execution or margins. UBS and Jefferies Lower Views on Medtronic (MDT) Amid Diabetes Unit Changes
• Negative Sentiment: Coverage noting MDT is trading near recent lows and headlines about steeper intraday/closing drops can amplify bearish sentiment and short‑term selling pressure even if fundamentals show product progress. Medtronic Near Lows: S&P 500 Index Healthcare Story to Watch Medtronic (MDT) Falls More Steeply Than Broader Market

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).